Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 6/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 2/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480900 | 1.00 | CNR2 (0.36) | CNR2RETNSD2KCNH2IRAK4 | |
| SCHEMBL19358796 | 1.00 | CNR2 (0.36) | CNR2RETNSD2KCNH2IRAK4 | |
| SCHEMBL19358789 | 0.86 | DTYMK (0.43) | CNR2NSD2KCNH2IRAK4CHRM2 | |
| SCHEMBL29480889 | 0.86 | DTYMK (0.43) | CNR2NSD2KCNH2IRAK4CHRM2 | |
| SCHEMBL17596556 | 0.85 | GPR119 (0.40) | CNR2NSD2IRAK4CETPGPR119 | |
| SCHEMBL16156345 | 0.85 | PLK1 (0.42) | CNR2NSD2KCNH2CHRM2CHRM4 | |
| SCHEMBL31579034 | 0.83 | CNR2 (0.44) | CNR2NSD2KCNH2CHRM2CHRM4 | |
| SCHEMBL31578956 | 0.80 | KDM4E (0.36) | — | |
| SCHEMBL17596606 | 0.78 | GPR119 (0.37) | CNR2RETGPR119 | |
| SCHEMBL19358788 | 0.77 | SETD7 (0.37) | IRAK4CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4472637-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | Kura Oncology, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023150635-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150635-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2019060365-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | MEN1, ABCB1, ABCC1 | CNR2 4864/4885RET 1100/4885NSD2 1585/4885 |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | CNR2 4601/4885RET 495/4885NSD2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.